Tesamorelin 10mg
Tesamorelin – a stabilized GHRH analog studied for GH release, IGF-1, and visceral fat tissue. Price and batch analysis.
59.00 EUR · In stock
This product is intended solely for scientific and research use, as well as for use as a reference standard in HPLC analysis, and is not an approved medicinal product. It is not intended for the diagnosis, treatment or prevention of disease in humans or animals. It has not been approved by the FDA, the EMA or any national regulator. The information on this page is provided for scientific information purposes only and does not constitute medical advice, a recommendation for use, or any claim of clinical efficacy or safety.
Tesamorelin – what the peptide is
Tesamorelin is a stabilized analog of growth hormone-releasing hormone, built on the GHRH (1-44) sequence. A trans-3-hexenoic acid group is attached to it, whose role is to slow down the enzymatic degradation of the molecule.
Through this modification, the compound differs from Sermorelin, which reproduces only the first 29 amino acids and lacks a protective group. The difference is evident in stability and in how long the molecule remains in circulation.
Tesamorelin is among the most thoroughly documented GHRH analogs, as it has undergone regulatory evaluation for a specific clinical indication, which has required the collection of systematized data.
Mechanism of action
The molecule binds to the GHRH receptor in the anterior pituitary gland and triggers the release of growth hormone. The release remains subject to natural regulation, including the inhibitory action of somatostatin.
The attached fatty acid group slows degradation by dipeptidyl peptidase-4 – the main inactivation pathway of natural GHRH. This accounts for the longer time profile compared to unmodified analogs.
The increase in IGF-1 occurs secondarily, following the release of growth hormone, and serves as an integrated indicator of the effect on the axis.
Research data and observations
Published observations track growth hormone and IGF-1 concentrations, as well as changes in fat tissue distribution. It is noted that visceral and subcutaneous fat tissue are affected differently.
Data on the compound are more systematized than those for most other peptides in the category, as they come from controlled studies with defined endpoints.
The response varies between individual participants, which is attributed to differences in pituitary reserve and baseline metabolic status.
When interpreting published data, the difference between preclinical and clinical conditions should be taken into account. Results from cell cultures and animal models describe a mechanism but do not allow quantitative conclusions for human conditions.
Dose ranges used in preclinical studies are often not directly translatable due to differences in metabolism between species. This limitation is consistently noted in review papers.
Example calculations
The calculations below are solely mathematical examples showing the relationship between the total amount of substance, solvent volume, and resulting concentration. They do not represent a dosing recommendation, administration schedule, or instructions for use.
When reconstituting 10 mg with 2 ml bacteriostatic water:
The resulting concentration is 5 mg/ml, with 0.20 ml containing 1 mg of substance.
Example values:
- 0.1 ml = 0.5 mg
- 0.2 ml = 1 mg
- 0.3 ml = 1.5 mg
- 0.4 ml = 2 mg
- 0.5 ml = 2.5 mg
Overview of scientific publications
The literature on Tesamorelin includes controlled studies lasting over one year – something that sets it apart from compounds in the group documented mainly in preclinical models.
The results apply to the specific studied population and are not automatically transferable to other conditions.
Safety data from the studies
The literature describes injection site reactions, edema, and joint pain, which are associated with elevated growth hormone levels. An effect on glucose metabolism is also noted.
The profile is among the better documented in this group precisely because there are controlled studies.
The general limitation for compounds in this category is the absence of long-term controlled studies in humans. The available information describes mechanism and short-term observations, not a safety profile for prolonged use.
The product is intended exclusively for research purposes. It is not a food, dietary supplement, or medicinal product and is not intended for the diagnosis, treatment, or prevention of disease.